At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
SLNO Soleno Therapeutics
Market Closed 05-17 16:00:00 EDT
46.16
+0.50
+1.10%
盘后46.16
+0.000.00%
16:02 EDT
High46.82
Low44.53
Vol334.44K
Open45.42
D1 Closing45.66
Amplitude5.02%
Mkt Cap1.68B
Tradable Cap784.87M
Total Shares36.41M
T/O15.36M
T/O Rate1.97%
Tradable Shares17.00M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Soleno Therapeutics Stands with the Prader-Willi Syndrome Community
While institutions invested in Soleno Therapeutics, Inc. (NASDAQ:SLNO) benefited from last week's 4.8% gain, private equity firms stood to gain the most
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.